Berbamine

Berbamine at a Glance

Berbamine is a bisbenzylisoquinoline alkaloid from barberry root bark — a larger, structurally distinct molecule from berberine, with which it shares a plant but not a mechanism.

Its defining property is inhibition of CaMKII-gamma, an unusual and specific target, and it carries a substantial preclinical anti-leukaemia literature — including activity in imatinib-resistant chronic myeloid leukaemia, which is the finding that has kept interest in it alive.

It also has a long, real history of medical use in China, where berbamine hydrochloride tablets are given to raise white-cell counts after chemotherapy or radiotherapy.

One caution comes before any of it: in 2025 two independent groups found that commercial material sold as berbamine is very often its isomer oxyacanthine.

The Bisbenzylisoquinoline Class

Berbamine belongs to a small, chemically distinctive alkaloid family whose members keep turning up in unrelated medicinal plants — oxyacanthine beside it in barberry root, tetrandrine in Stephania and abuta, tubocurarine in curare.

What a bisbenzylisoquinoline is. Take two benzylisoquinoline units — the same C₁₆ building block that leads to morphine in one direction and berberine in another — and join them head-to-head and tail-to-tail through diaryl ether bridges. The result is a large, rigid, doubly basic macrocycle of roughly 600–625 Da. That size is the class’s defining practical fact: bisBIQ alkaloids are poorly water-soluble, poorly absorbed by mouth, heavily bound to plasma protein, and strong substrates and inhibitors of P-glycoprotein ^{13Reference 13Zhang H et al. · 2021ReviewThirteen bisbenzylisoquinoline alkaloids in five Chinese medicinal plants: botany, traditional uses, phytochemistry, pharmacokinetics and toxicity — reviewView study →}.

The three barberry-and-relatives molecules line up like this:

Molecule	Formula	Mass	Relationship
Berbamine	C₃₇H₄₀N₂O₆	608.7	free phenol on one aromatic ring
Oxyacanthine	C₃₇H₄₀N₂O₆	608.7	same formula and mass as berbamine — an isomer, with the two ether bridges joining different carbons and the free phenol in a different position
Isotetrandrine	C₃₈H₄₂N₂O₆	622.7	berbamine’s O-methyl ether — the same skeleton and the same configuration, with that phenol capped as a methoxy
Tetrandrine	C₃₈H₄₂N₂O₆	622.7	the epimer of isotetrandrine — identical connectivity, opposite configuration at one benzylic carbon

So berbamine and tetrandrine are two methylation steps and one stereocentre apart, which is why their pharmacology overlaps and why it is not identical. Oxyacanthine is the odd one: same formula as berbamine, different plumbing.

What the class shares. Calcium-channel antagonism at the L-type channel, giving vasodilation, negative inotropy and smooth-muscle relaxation; P-glycoprotein inhibition, giving multidrug-resistance reversal in cancer models and drug-interaction potential in life; and a metabolic liability — bisBIQ alkaloids are bioactivated to quinone-methide intermediates, which is the proposed basis for the renal and hepatic toxicity reported at high exposure ^{13Reference 13Zhang H et al. · 2021ReviewThirteen bisbenzylisoquinoline alkaloids in five Chinese medicinal plants: botany, traditional uses, phytochemistry, pharmacokinetics and toxicity — reviewView study →}.

What the class does not share is its pharmacology beyond that. The muscle relaxant tubocurarine, the active principle of curare, is a bisbenzylisoquinoline; berbamine, oxyacanthine and tetrandrine are not neuromuscular blockers. One structural class, several unrelated therapeutic identities — the skeleton predicts the pharmacokinetics far better than it predicts the effect.

The Berbamine That Is Not Berbamine

Berbamine and oxyacanthine share a molecular formula, C₃₇H₄₀N₂O₆, a mass of 608.7, and enough structural similarity that mass spectrometry cannot separate them. They differ in where the two diaryl-ether bridges join the two halves and in where the free phenol sits — differences that only NMR or crystallography resolves.

In 2025 a group at the Chinese Academy of Sciences bought samples labelled “berbamine” from fourteen suppliers. All fourteen gave consistent NMR spectra, X-ray crystallography on one confirmed the structure, and all fourteen were oxyacanthine, not berbamine ^{20Reference 20Cheng Y et al. · 2025Structural similarity in natural products leading to sample misidentification: a case study of the bisbenzylisoquinoline alkaloids oxyacanthine and berbamineView study →}. To obtain genuine berbamine for comparison the authors had to isolate it themselves from Berberis sieboldii root — and in doing so published the first crystal structure of the real compound. Independently, a second group used microcrystal electron diffraction to solve two polymorphs of oxyacanthine dihydrochloride monohydrate from samples “mislabelled as berbamine dihydrochloride” ^{22Reference 22Lin J et al. · 2026Discovery of oxyacanthine dihydrochloride monohydrate polymorphs from obfuscated samples by microcrystal electron diffractionView study →}.

Later the same year, the first asymmetric total synthesis of both alkaloids confirmed the misidentification a third way, by making authentic berbamine and authentic oxyacanthine from a common route ^{21Reference 21Xiang L et al. · 2025In vitroAsymmetric total synthesis and anti-inflammatory activity of berbamine, oxyacanthine, and related intermediates — in vitroView study →}.

What this does and does not mean. It does not invalidate the berbamine literature: much of the oncology work used material the authors isolated and characterised themselves, and where the two alkaloids have been compared directly their activities often run parallel — in the synthesis paper both suppressed IL-6 and IL-1β in stimulated macrophages to a comparable degree ^{21Reference 21Xiang L et al. · 2025In vitroAsymmetric total synthesis and anti-inflammatory activity of berbamine, oxyacanthine, and related intermediates — in vitroView study →}. What it does mean is that any berbamine result obtained with purchased compound has an identity question attached to it until the material is checked, and that the two molecules’ pharmacological reputations may be more entangled than the separate literatures suggest.

Berbamine vs. Berberine

Barberry root is famous for berberine, and on the herb’s most human-evidenced use berberine appears not to be the molecule doing the work.

The two are not close relatives. Berberine is a small, flat, permanently charged quaternary protoberberine of 336 Da, intensely yellow, and it dominates barberry’s roughly 4% total-alkaloid fraction ^{18Reference 18Mokhber-Dezfuli N et al. · 2014ReviewPhytochemistry and pharmacology of Berberis species — reviewView study →}. Berbamine is nearly twice the mass, uncharged, colourless, and a minor component of that same fraction. They share a root and a biosynthetic origin and almost nothing else: berberine’s reputation is metabolic and antimicrobial, berbamine’s is oncological and cardiovascular.

The point where this matters is psoriasis. Mahonia aquifolium (Oregon grape) cream has the only clinical evidence any Berberis-family plant has for a skin indication ^{12Reference 12Gulliver WP · 2005Clinical trialA report on three recent clinical trials using Mahonia aquifolium 10% topical cream and a review of the worldwide clinical experienceView study →}, and the activity has been attributed to the bisbenzylisoquinoline fraction rather than to berberine — with numbers behind it. Mahonia bark extract inhibits human keratinocyte growth with an IC50 of 35 µM; berberine matches the extract; berbamine and oxyacanthine are three times more potent than either ^{23Reference 23Müller K et al. · 1995In vitroThe antipsoriatic Mahonia aquifolium and its active constituents; IIView study →}. Of six Mahonia bisbenzylisoquinolines tested for lipoxygenase inhibition — the enzyme family whose products are implicated in psoriasis — berbamine and oxyacanthine were again the two most potent ^{24Reference 24Bezáková L et al. · 1996In vitroLipoxygenase inhibition and antioxidant properties of bisbenzylisoquinoline alkaloids isolated from Mahonia aquifolium — in vitroView study →}.

A reader who reasons “barberry means berberine” gets the wrong molecule for that use.

What It's Used For

Berbamine is the most-studied member of the barberry bisBIQ family, and its distinctive hook is that it is one of very few natural products shown to bind and inhibit CaMKIIγ, a kinase active in leukaemia stem cells. It also has real, longstanding human use in China as an oral agent to raise white-cell counts, though that legacy use is not RCT-grade.

Evidence by IndicationStrength of support · Beta

01Anticancer / anti-leukemiaPromising45%CaMKIIγ + Bcr-Abl killing across CML/myeloma models ^{1,2,3,4,5,6Reference 1Gu Y et al. · 2012CaMKIIγ, a critical regulator of CML stem/progenitor cells, is a target of the natural product berbamineView study →Reference 2Xu R et al. · 2006Berbamine: a novel inhibitor of bcr/abl fusion gene with potent anti-leukemia activityView study →Reference 3Wei YL et al. · 2009In vitroBerbamine exhibits potent antitumor effects on imatinib-resistant CML cells in vitro and in vivoView study →Reference 4Liang Y et al. · 2009Berbamine, a novel nuclear factor-κB inhibitor, inhibits growth and induces apoptosis in human myeloma cellsView study →Reference 5Meng Z et al. · 2013Berbamine inhibits the growth of liver cancer cells and cancer-initiating cells by targeting Ca²⁺/calmodulin-dependent protein kinase IIView study →Reference 6Muhammad G et al. · 2025ReviewPharmacological and therapeutic potential of berbamine: a potent alkaloid from the genus Berberis — reviewView study →}

02Cardiovascular / antiarrhythmicShaky30%bisBIQ Ca-channel action, an early hypotension study, and the N-methyl derivative ^{7,8,9,15Reference 7Guo ZB et al. · 2005ReviewGuo ZB, Fu JG, et al. (2005). [Progress of cardiovascular pharmacologic study on berbamine] — review. Zhongguo Zhong Xi Yi Jie He Za Zhi. https://pubmed.ncbi.nlm.nih.gov/16152843/View study →Reference 8Qian JQ et al. · 2002Cardiovascular pharmacological effects of bisbenzylisoquinoline alkaloid derivativesView study →Reference 9Hu H et al. · 2020A potent antiarrhythmic drug N-methyl berbamine extends the action potential through inhibiting both calcium and potassium currentsView study →Reference 15Khan I et al. · 1969AnimalStudy of the hypotensive action of berbamine, an alkaloid isolated from Berberis lycium — animal in vivoView study →}

03Anti-inflammatory / immunomodulatoryShaky25%Legacy leukopenia use + NF-κB/macrophage data ^{4,10,11Reference 4Liang Y et al. · 2009Berbamine, a novel nuclear factor-κB inhibitor, inhibits growth and induces apoptosis in human myeloma cellsView study →Reference 10Kapoor S et al. · 2012ReviewEmerging role of berbamine as an anti-cancer agent in systemic malignancies besides chronic myeloid leukemia — reviewView study →Reference 11Ma JY et al. · 1992In vitroInhibition of respiratory-burst activity in alveolar macrophages by bisbenzylisoquinoline alkaloids — in vitroView study →}

Mechanisms

Directly measured for berbamine itself: CaMKIIγ inhibition, NF-κB blockade, Bcr-Abl-clone killing, Ca²⁺-channel effects and hypotension. Jak2/Stat3 potency figures largely reflect the engineered derivatives; the P-gp row is class-level.

Pharmacokinetics

There is no robust modern human PK dataset for berbamine, and it is not one of the thirteen bisbenzylisoquinolines with published pharmacokinetic parameters — so what follows is class inference, stated as such. As a large dimeric bisBIQ it shares the class profile of poor aqueous solubility, low and variable oral bioavailability, strong plasma-protein binding and strong P-glycoprotein affinity ^{13Reference 13Zhang H et al. · 2021ReviewThirteen bisbenzylisoquinoline alkaloids in five Chinese medicinal plants: botany, traditional uses, phytochemistry, pharmacokinetics and toxicity — reviewView study →} — the same limitation that keeps the anticancer data preclinical and motivates the nanoparticle/derivative delivery work ^{6Reference 6Muhammad G et al. · 2025ReviewPharmacological and therapeutic potential of berbamine: a potent alkaloid from the genus Berberis — reviewView study →}. Distribution is expected to be wide with hepatic handling typical of lipophilic bisBIQ alkaloids, and the class is metabolised in part to reactive quinone-methide intermediates ^{13Reference 13Zhang H et al. · 2021ReviewThirteen bisbenzylisoquinoline alkaloids in five Chinese medicinal plants: botany, traditional uses, phytochemistry, pharmacokinetics and toxicity — reviewView study →}. Specific human ADME parameters are not established. Within whole barberry root, berbamine exposure is minor and dominated by berberine.

Clinical trials

Berbamine has real, longstanding human use in China as a white-blood-cell-raising (leukopenia) agent and is an approved product there — but this is legacy clinical/regulatory practice, not a modern rigorous randomized controlled trial. For the marquee anticancer, cardiovascular and anti-inflammatory indications, the evidence is preclinical only.

Last checked: September 2026.

Isolate vs. Plant Studies

The split here is unusually clean, and it runs in opposite directions for the two halves of berbamine’s reputation.

The oncology evidence is all isolate. CaMKIIγ binding, Bcr-Abl downregulation, myeloma apoptosis, the xenografts — every one used purified berbamine or a synthetic derivative at concentrations no barberry preparation delivers ^{1,2,3,4,5,6Reference 1Gu Y et al. · 2012CaMKIIγ, a critical regulator of CML stem/progenitor cells, is a target of the natural product berbamineView study →Reference 2Xu R et al. · 2006Berbamine: a novel inhibitor of bcr/abl fusion gene with potent anti-leukemia activityView study →Reference 3Wei YL et al. · 2009In vitroBerbamine exhibits potent antitumor effects on imatinib-resistant CML cells in vitro and in vivoView study →Reference 4Liang Y et al. · 2009Berbamine, a novel nuclear factor-κB inhibitor, inhibits growth and induces apoptosis in human myeloma cellsView study →Reference 5Meng Z et al. · 2013Berbamine inhibits the growth of liver cancer cells and cancer-initiating cells by targeting Ca²⁺/calmodulin-dependent protein kinase IIView study →Reference 6Muhammad G et al. · 2025ReviewPharmacological and therapeutic potential of berbamine: a potent alkaloid from the genus Berberis — reviewView study →}. Berbamine is a minor alkaloid inside a berberine-dominated extract; nothing about drinking barberry root approximates these experiments. The Chinese leukopenia indication is also an isolate: berbamine hydrochloride tablets, a defined single compound at a defined dose ^{10Reference 10Kapoor S et al. · 2012ReviewEmerging role of berbamine as an anti-cancer agent in systemic malignancies besides chronic myeloid leukemia — reviewView study →}.

The only plant-level human evidence points the other way. Mahonia aquifolium 10% topical cream has been through several clinical trials in psoriasis ^{12Reference 12Gulliver WP · 2005Clinical trialA report on three recent clinical trials using Mahonia aquifolium 10% topical cream and a review of the worldwide clinical experienceView study →} — whole-plant, topical, and impossible to apportion to any one alkaloid. Berbamine’s role in it is a mechanistic attribution to the bisbenzylisoquinoline fraction, not a measured contribution.

So: a molecule with real human dosing, real preclinical depth, and no study anywhere that connects the two — no trial has given isolated berbamine for cancer, and no trial has shown that a barberry preparation delivers enough berbamine to matter.

Its Role in Plants

Bisbenzylisoquinoline biosynthesis was worked out in Berberis itself, and it is one of the more elegant pieces of plant enzymology.

The dimer is assembled by berbamunine synthase, a cytochrome P450 (CYP80A1) cloned from cell suspension cultures of Berberis stolonifera ^{14Reference 14Kraus PF · 1995Molecular cloning and heterologous expression of a cDNA encoding berbamunine synthase, a C–O phenol-coupling cytochrome P450 from the higher plant Berberis stoloniferaView study →}. It is unusual among P450s in acting as an oxidase rather than a monooxygenase — it forms the carbon–oxygen phenol couple between two benzylisoquinoline units without inserting oxygen into the product, and the protein carries a proline where the classic oxygen-binding glycine sits in bacterial P450cam. Expressed in insect cells, the enzyme couples either two molecules of (R)-N-methylcoclaurine, giving the (R,R) dimer guattegaumerine, or one (R) and one (S) molecule, giving the (R,S) dimer berbamunine — and the ratio shifts with the enantiomer supply ^{14Reference 14Kraus PF · 1995Molecular cloning and heterologous expression of a cDNA encoding berbamunine synthase, a C–O phenol-coupling cytochrome P450 from the higher plant Berberis stoloniferaView study →}.

That is the whole logic of the class in one experiment: which dimer a plant makes is decided by which enantiomers the enzyme is fed and how it orients them, which is why Berberis accumulates a mixture of closely related isomers — berbamine, oxyacanthine, isotetrandrine — rather than one clean product.

The ecological rationale is the ordinary one for root-bark alkaloids: they sit in the perennial storage tissue rather than the leaf or fruit, and the fruit of the same plants is alkaloid-poor and edible.

Prevalence in Nature

Bisbenzylisoquinoline alkaloids occur mainly in the Berberidaceae, Menispermaceae, Monimiaceae and Ranunculaceae, concentrated in tropical and subtropical genera ^{13Reference 13Zhang H et al. · 2021ReviewThirteen bisbenzylisoquinoline alkaloids in five Chinese medicinal plants: botany, traditional uses, phytochemistry, pharmacokinetics and toxicity — reviewView study →}. Berbamine is a Berberidaceae alkaloid specifically, and within those plants a root and root-bark constituent rather than a leaf or fruit one.

It has been reported from Berberis vulgaris (barberry) ^{18Reference 18Mokhber-Dezfuli N et al. · 2014ReviewPhytochemistry and pharmacology of Berberis species — reviewView study →}, B. lycium ^{15Reference 15Khan I et al. · 1969AnimalStudy of the hypotensive action of berbamine, an alkaloid isolated from Berberis lycium — animal in vivoView study →}, B. asiatica ^{19Reference 19Joshi T et al. · 2021Identification of berbamine, oxyacanthine and rutin from Berberis asiatica as anti-SARS-CoV-2 compounds: an in-silico studyView study →}, B. amurensis and B. poiretii, and from Mahonia aquifolium (Oregon grape), where it is part of the bisbenzylisoquinoline fraction credited with the plant’s antipsoriatic activity ^{12Reference 12Gulliver WP · 2005Clinical trialA report on three recent clinical trials using Mahonia aquifolium 10% topical cream and a review of the worldwide clinical experienceView study →}.

Quantitatively it is not well characterised. Barberry root carries roughly 4% total alkaloids and that fraction is dominated by berberine ^{18Reference 18Mokhber-Dezfuli N et al. · 2014ReviewPhytochemistry and pharmacology of Berberis species — reviewView study →}; berbamine’s own share is described as minor in every source but has not been published as a percentage that could be compared across species or tissues. Isolated berbamine used in research and in the Chinese tablet product is purified material, so the plant figure has never been on anyone’s critical path.

Major Natural Sources

Source	Part	Level	Note
Barberry (Berberis vulgaris)	root, root bark	minor within a ~4% total-alkaloid fraction	berberine-dominated; berbamine not separately quantified 18Reference 18Mokhber-Dezfuli N et al. · 2014ReviewPhytochemistry and pharmacology of Berberis species — reviewView study →
Berberis lycium	root	not quantified	the source material for the 1969 hypotension work 15Reference 15Khan I et al. · 1969AnimalStudy of the hypotensive action of berbamine, an alkaloid isolated from Berberis lycium — animal in vivoView study →
Berberis asiatica	root	not quantified	co-reported with oxyacanthine and rutin 19Reference 19Joshi T et al. · 2021Identification of berbamine, oxyacanthine and rutin from Berberis asiatica as anti-SARS-CoV-2 compounds: an in-silico studyView study →
Oregon grape (Mahonia aquifolium)	root, bark	not quantified	the bisBIQ fraction credited with the antipsoriatic effect 12Reference 12Gulliver WP · 2005Clinical trialA report on three recent clinical trials using Mahonia aquifolium 10% topical cream and a review of the worldwide clinical experienceView study →
Berberis amurensis, B. poiretii	root	not quantified	further Berberis sources

Discovery & Synthesis

Berbamine is one of the older Berberis alkaloids, described during the long nineteenth- and twentieth-century working-out of barberry chemistry; a single first-isolation date and discoverer are not reliably established in the accessible record. Its first measured pharmacology is clearer — a 1969 study of the hypotensive action of berbamine isolated from Berberis lycium ^{15Reference 15Khan I et al. · 1969AnimalStudy of the hypotensive action of berbamine, an alkaloid isolated from Berberis lycium — animal in vivoView study →} — and its modern identity dates from the 1970s, when berbamine hydrochloride tablets were introduced in China for chemotherapy- and radiotherapy-induced leukopenia ^{10Reference 10Kapoor S et al. · 2012ReviewEmerging role of berbamine as an anti-cancer agent in systemic malignancies besides chronic myeloid leukemia — reviewView study →}.

The chemistry stayed unfinished for a surprisingly long time. Closing a macrocyclic bis-diaryl-ether while controlling two benzylic stereocentres is hard: a 2020 modular route reached tetrandrine and isotetrandrine — isotetrandrine being berbamine’s own O-methyl ether — from separately prepared halves ^{17Reference 17Schütz R et al. · 2020A modular approach to the bisbenzylisoquinoline alkaloids tetrandrine and isotetrandrineView study →}, and the first asymmetric total synthesis of berbamine itself followed only in 2025, using Noyori asymmetric hydrogenation to install the stereocentres and copper-mediated Ullmann coupling to close the ring ^{21Reference 21Xiang L et al. · 2025In vitroAsymmetric total synthesis and anti-inflammatory activity of berbamine, oxyacanthine, and related intermediates — in vitroView study →}. The same sequence produced oxyacanthine, which is how it settled the misidentification question.

Supply is still extraction, not synthesis. Berbamine is isolated from Berberis root, and the isolate is the starting point for the derivative programmes — N-methyl berbamine for the antiarrhythmic work ^{9Reference 9Hu H et al. · 2020A potent antiarrhythmic drug N-methyl berbamine extends the action potential through inhibiting both calcium and potassium currentsView study →} and the BBMD3 series for oncology ^{6Reference 6Muhammad G et al. · 2025ReviewPharmacological and therapeutic potential of berbamine: a potent alkaloid from the genus Berberis — reviewView study →}. The synthetic route matters for a different reason: it is now possible to obtain berbamine of certain identity without trusting a supplier ^{20,21Reference 20Cheng Y et al. · 2025Structural similarity in natural products leading to sample misidentification: a case study of the bisbenzylisoquinoline alkaloids oxyacanthine and berbamineView study →Reference 21Xiang L et al. · 2025In vitroAsymmetric total synthesis and anti-inflammatory activity of berbamine, oxyacanthine, and related intermediates — in vitroView study →}.

Patents: not yet researched (future patent-loop pass).

Toxicity & Safety

What separates berbamine from its quieter bisBIQ cousins is that it is genuinely cardioactive and genuinely dosed in people — the ion-channel effects that make it an antiarrhythmic candidate are the same ones that make it a cardiac caution.

Safety at a Glance

⚠️ Moderate toxicityCardiac cautionDrug interactions

• Blocks cardiac calcium and hERG potassium currents. Action-potential prolongation is a recognized proarrhythmic-liability signal.
• Avoid in pregnancy and breastfeeding. Class reproductive concern and no isolate data.
• Additive risk with cardioactive or QT-prolonging drugs. Theoretical hypotensive and QT effects stack.
• P-glycoprotein inhibition is a class property. It can raise blood levels of co-administered P-gp substrate drugs.
• The bisBIQ class is broadly cardioactive. Calcium antagonism, negative inotropy and hypotension come with the chemistry.
• Long tolerated oral use at leukopenia doses. No high-flag organ-toxicity signal at the established Chinese dosing.

Full Safety & Interactions Detail

Two things separate berbamine from the quieter alkaloids beside it in barberry root: real human systemic exposure as a marketed oral drug, and documented cardioactivity. Berbamine and its N-methyl derivative block cardiac Ca²⁺ (Cav1.2) and K⁺ (Kv11.1/hERG) currents and prolong the action potential ^{9Reference 9Hu H et al. · 2020A potent antiarrhythmic drug N-methyl berbamine extends the action potential through inhibiting both calcium and potassium currentsView study →} — the hERG interaction being a recognised proarrhythmic-liability signal — and the bisbenzylisoquinoline class is broadly cardioactive, with calcium antagonism, negative inotropy and hypotension ^{7,8Reference 7Guo ZB et al. · 2005ReviewGuo ZB, Fu JG, et al. (2005). [Progress of cardiovascular pharmacologic study on berbamine] — review. Zhongguo Zhong Xi Yi Jie He Za Zhi. https://pubmed.ncbi.nlm.nih.gov/16152843/View study →Reference 8Qian JQ et al. · 2002Cardiovascular pharmacological effects of bisbenzylisoquinoline alkaloid derivativesView study →}, an effect measured for berbamine itself as far back as 1969 ^{15Reference 15Khan I et al. · 1969AnimalStudy of the hypotensive action of berbamine, an alkaloid isolated from Berberis lycium — animal in vivoView study →}.

Oxyacanthine, by contrast, has neither human dosing nor measured cardiac data, and tetrandrine has both plus documented organ accumulation. Against that, berbamine’s established leukopenia doses have a long history of tolerated oral use with no high-flag organ-toxicity signal.

Two interaction routes follow from the chemistry rather than from any study of berbamine. Bisbenzylisoquinolines are strong P-glycoprotein inhibitors, so they can raise blood levels of co-administered P-gp substrates ^{13Reference 13Zhang H et al. · 2021ReviewThirteen bisbenzylisoquinoline alkaloids in five Chinese medicinal plants: botany, traditional uses, phytochemistry, pharmacokinetics and toxicity — reviewView study →}.

The class is metabolised in part to reactive quinone-methide intermediates, the proposed basis for the renal and hepatic toxicity reported for bisBIQ alkaloids at high exposure ^{13Reference 13Zhang H et al. · 2021ReviewThirteen bisbenzylisoquinoline alkaloids in five Chinese medicinal plants: botany, traditional uses, phytochemistry, pharmacokinetics and toxicity — reviewView study →}.

Neither has been characterised for berbamine specifically. Practical caveats: theoretical additive cardiovascular/hypotensive and QT effects with cardioactive or QT-prolonging drugs.

Dosage

There is no validated Western supplement dose, and nothing here is a recommendation.

Berbamine is not sold as a general isolated nutraceutical in most markets. The leukopenia figure is a specific medical use under supervision, not a self-care dose. These are doses studied in research and are not a personal recommendation.

References

1. Gu Y, et al. (2012). CaMKIIγ, a critical regulator of CML stem/progenitor cells, is a target of the natural product berbamine. Blood. https://pubmed.ncbi.nlm.nih.gov/23074277/
2. Xu R, et al. (2006). Berbamine: a novel inhibitor of bcr/abl fusion gene with potent anti-leukemia activity. Leukemia Research. https://pubmed.ncbi.nlm.nih.gov/16023722/
3. Wei YL, et al. (2009). Berbamine exhibits potent antitumor effects on imatinib-resistant CML cells in vitro and in vivo. Acta Pharmacologica Sinica. https://pubmed.ncbi.nlm.nih.gov/19270722/
4. Liang Y, et al. (2009). Berbamine, a novel nuclear factor-κB inhibitor, inhibits growth and induces apoptosis in human myeloma cells. Acta Pharmacologica Sinica. https://pubmed.ncbi.nlm.nih.gov/19960011/
5. Meng Z, et al. (2013). Berbamine inhibits the growth of liver cancer cells and cancer-initiating cells by targeting Ca²⁺/calmodulin-dependent protein kinase II. Molecular Cancer Therapeutics. https://pubmed.ncbi.nlm.nih.gov/23960096/
6. Muhammad G, Hussain MA, Shafiq Z, et al. (2025). Pharmacological and therapeutic potential of berbamine: a potent alkaloid from the genus Berberis — review. Current Topics in Medicinal Chemistry. https://pubmed.ncbi.nlm.nih.gov/38685780/
7. Guo ZB, Fu JG, et al. (2005). [Progress of cardiovascular pharmacologic study on berbamine] — review. Zhongguo Zhong Xi Yi Jie He Za Zhi. https://pubmed.ncbi.nlm.nih.gov/16152843/
8. Qian JQ, et al. (2002). Cardiovascular pharmacological effects of bisbenzylisoquinoline alkaloid derivatives. Acta Pharmacologica Sinica. https://pubmed.ncbi.nlm.nih.gov/12466045/
9. Hu H, Zhou S, Sun X, et al. (2020). A potent antiarrhythmic drug N-methyl berbamine extends the action potential through inhibiting both calcium and potassium currents. Journal of Pharmacological Sciences. https://pubmed.ncbi.nlm.nih.gov/31992491/
10. Kapoor S, et al. (2012). Emerging role of berbamine as an anti-cancer agent in systemic malignancies besides chronic myeloid leukemia — review. Journal of Zhejiang University-Science B. https://pubmed.ncbi.nlm.nih.gov/22949368/
11. Ma JY, Barger MW, Ma JK, et al. (1992). Inhibition of respiratory-burst activity in alveolar macrophages by bisbenzylisoquinoline alkaloids — in vitro. Experimental Lung Research. https://pubmed.ncbi.nlm.nih.gov/1361431/
12. Gulliver WP, Donsky HJ (2005). A report on three recent clinical trials using Mahonia aquifolium 10% topical cream and a review of the worldwide clinical experience. American Journal of Therapeutics. https://pubmed.ncbi.nlm.nih.gov/16148424/
13. Zhang H, Wang X, Guo Y, et al. (2021). Thirteen bisbenzylisoquinoline alkaloids in five Chinese medicinal plants: botany, traditional uses, phytochemistry, pharmacokinetics and toxicity — review. Journal of Ethnopharmacology. https://pubmed.ncbi.nlm.nih.gov/33166629/
14. Kraus PF, Kutchan TM (1995). Molecular cloning and heterologous expression of a cDNA encoding berbamunine synthase, a C–O phenol-coupling cytochrome P450 from the higher plant Berberis stolonifera. Proceedings of the National Academy of Sciences. https://pubmed.ncbi.nlm.nih.gov/7892226/
15. Khan I, Qayum A, Qureshi Z (1969). Study of the hypotensive action of berbamine, an alkaloid isolated from Berberis lycium — animal in vivo. Life Sciences. https://doi.org/10.1016/0024-3205(69)90432-9
16. Wong C, Seow W, Zeng T, et al. (1991). Comparative immunopharmacology and toxicology of the bisbenzylisoquinoline alkaloids tetrandrine and berbamine — in vitro. International Journal of Immunopharmacology. https://doi.org/10.1016/0192-0561(91)90079-m
17. Schütz R, Meixner M, Antes I, et al. (2020). A modular approach to the bisbenzylisoquinoline alkaloids tetrandrine and isotetrandrine. Organic & Biomolecular Chemistry. https://doi.org/10.1039/d0ob00078g
18. Mokhber-Dezfuli N, Saeidnia S, Gohari AR, et al. (2014). Phytochemistry and pharmacology of Berberis species — review. Pharmacognosy Reviews. https://pubmed.ncbi.nlm.nih.gov/24600191/
19. Joshi T, Bhat S, Pundir H, et al. (2021). Identification of berbamine, oxyacanthine and rutin from Berberis asiatica as anti-SARS-CoV-2 compounds: an in-silico study. Journal of Molecular Graphics and Modelling. https://pubmed.ncbi.nlm.nih.gov/34649146/
20. Cheng Y, Akramov D, Yakhshilikova L, et al. (2025). Structural similarity in natural products leading to sample misidentification: a case study of the bisbenzylisoquinoline alkaloids oxyacanthine and berbamine. Journal of Natural Products. https://pubmed.ncbi.nlm.nih.gov/39787003/
21. Xiang L, Qin J, Kushatov T, et al. (2025). Asymmetric total synthesis and anti-inflammatory activity of berbamine, oxyacanthine, and related intermediates — in vitro. Journal of Natural Products. https://pubmed.ncbi.nlm.nih.gov/41292297/
22. Lin J, Paz O, Unge J, et al. (2026). Discovery of oxyacanthine dihydrochloride monohydrate polymorphs from obfuscated samples by microcrystal electron diffraction. ChemMedChem. https://pubmed.ncbi.nlm.nih.gov/41388184/
23. Müller K, Ziereis K, Gawlik I (1995). The antipsoriatic Mahonia aquifolium and its active constituents; II. Antiproliferative activity against cell growth of human keratinocytes — in vitro. Planta Medica. https://pubmed.ncbi.nlm.nih.gov/7700998/
24. Bezáková L, Misik V, Máleková L, et al. (1996). Lipoxygenase inhibition and antioxidant properties of bisbenzylisoquinoline alkaloids isolated from Mahonia aquifolium — in vitro. Pharmazie. https://pubmed.ncbi.nlm.nih.gov/8941945/

View all 24 references▾